

Table 2. Progression-free survival. Results of pairwise comparisons with sunitinib (intermediate and poor risk groups according to the International Metastatic RCC Database Consortium)

Intervention	RCT number (name)	IMDC risk group	Risk of Bias*	Progression-free survival HR [95% CI]	Clinically relevant in favour of
Avelumab + Axitinib	NCT02684006 (Javelin renal 101)	intermediate	High (D3, 5)	0.71 [0.58, 0.87]	Avelumab + Axitinib
		poor		0.45 [0.30, 0.67]	Avelumab + Axitinib
Lenvantinib + Pembrolizumab	NCT02811861a (CLEAR)	intermediate	High (D3, 4)	0.39 [0.29, 0.52]	Lenvantinib + Pembrolizumab
Nivolumab + Ipilimumab	NCT02231749 (Checkmate 214)	intermediate-poor	High (D4)	0.74 [0.62, 0.88]	Nivolumab + Ipilimumab
Cabozantinib	NCT01835158 (CABOSUN)	intermediate	Some concerns (D5)	0.52 [0.32, 0.83]	Cabozantinib
		poor		0.31 [0.11, 0.90]	Cabozantinib
Lenvantinib + Everolimus	NCT02811861b (CLEAR)	intermediate	High (D3, 4)	0.67 [0.51, 0.88]	Lenvantinib + Everolimus
		poor		0.73 [0.42, 1.28]	Lenvantinib + Everolimus

* D1 Bias arising from the randomization process

D2 Bias due to deviations from intended intervention

D3 Bias due to missing outcome data

D4 Bias in measurement of the outcome

D5 Bias in selection of the reported result